Like nausea, diarrhea tends to be dose-dependent and occurs most frequently during treatment initiation and dose increases
Gastrointestinal symptoms were the most common side effects
Horrell EMW, Boulanger MC, DOrazio JA
This is where a licensed provider reviews your medical information, evaluates your eligibility, and makes the clinical decision about whether to prescribe GLP-1 medication
KEY BENEFITS FROM RESEARCH Enhances cell migration to injury sites Improves wound healing and tissue repair Supports new blood vessel formation Reduces tissue inflammation May support cardiovascular health KPV: THE INFLAMMATION CONTROLLER WHAT IT IS KPV is a tiny three-amino acid peptide (Lysine-Proline-Valine) that comes from a larger hormone that controls inflammation
Gastrointestinal side effects are by far the most prevalent during early treatment: Nausea Very common (may affect more than 1 in 10 people), typically peaking during the first week and often improving over two to four weeks [1] [2] Vomiting Common (may affect up to 1 in 10 people), usually occurring alongside nausea [1] [2] Diarrhoea Common, may persist for several weeks Constipation Common, sometimes alternating with diarrhoea Abdominal pain or discomfort Common, ranging from mild cramping to more pronounced discomfort Dyspepsia (indigestion) Common Eructation (belching) Common Reduced appetite A therapeutic effect that may feel uncomfortable initially, affecting eating patterns These symptoms arise because semaglutide mimics the natural GLP-1 hormone, which slows gastric emptying and increases satiety
